Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva Pharmaceutical Industries Ltd.

www.tevapharm.com

Latest From Teva Pharmaceutical Industries Ltd.

Generic Abuse-Deterrent Opioids: Comparison To Brand Will Not Require Use Of Control

FDA final guidance recommends comparative pharmacodynamic studies for nasal and oral routes of abuse, simplifies statistical approach to show deterrence of generic is same as brand.

BioPharmaceutical Regulation

Keeping Track: A Second Straight Burst Of FDA Approvals

The latest drug approval and development news from our US FDA Performance Tracker.

Performance Tracker Drug Review

What's Behind The Success Of Korean Biosimilars?

Celltrion and Samsung Bioepis are moving fast to grab leading positions in the global biosimilars space, but how have these two firms got to where there are now? Scrip takes a look at what is driving their success and where they are heading next.

South Korea Biosimilars

AZ Looks To Lead Severe Asthma Market After US Fasenra OK

Following FDA approval, AstraZeneca believes that despite reaching the market after GlaxoSmithKline’s Nucala and Teva’s Cinqair, Fasenra's strong clinical package, convenient dosing and very competitive pricing will make it the leading biologic for severe asthma.

Respiratory Approvals
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register